Replies to post #36102 on Cel Sci Corporation (CVM)

[RobotDroid]

Here is another boards post on value....
Anonymous34 minutes ago
PART 2... OK kids, now Arithmetic class. MANDATORY READ. POSSIBLE STOCK GAIN 75x. IF data shows a 10% cure rate in 3 weeks prior to the Standard of “Care,” surgery / chemo / radiation, and 3 years added survival (based on 3 extra years until patient #298 died), Multikine will be the pre-treatment SoC for head & neck cancer – and a SUPER BLOCKBUSTER, for all cancer.

Immunomedics, IMMU, had its drug approved for one cancer, “to treat adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies.” But within 6 months, before IMMU had any sales, Gilead, GILD, paid $20 Billion, so it could get the drug approved for other cancers.

Celgene, CELG, had drugs, Liso-cel, an experimental treatment for lymphoma, and Zeposi for multiple sclerosis, and upon approval, before any sales, Bristol-Myers paid $74 Billion!

IF Multikine data show 10% cure, and 3 years survival, it will be far more valuable than the IMMU or CELG drugs, as each year, worldwide, 19 million people get cancer, with 2 million deaths. The USA annually has 1.8 million cancer cases with over 600,000 deaths. The US has 65,000 Head & Neck cancers cases, globally is the 6th most common cancers, and the #1 cancers in developing countries, Southeast Asia, India, and Europe. CVM, has partnerships with Teva, Orient, and Europharma, which will spearhead sales in Europe, Middle East, and Asia.

In time, when approved for multiple cancers, or off label use, or patients’ Right to Try choices, at $75,000 per patient (akin to an adjunct chemo drug; 75% discount to a chemo drug), with only 50% of US cases, sales will be $67 Billion – 3x GILD total sales, and +150% BMY total sales! Foreign sales will add tens of billions.

Multikine is to be given ASAP at cancer diagnosis. There are 13,000 oncologists – fairly simple logistics (think Amazon Prime), with solid profit margin, without ludicrous sales costs (as too many drug companies needlessly do).

Arithmetic 101 Cases: CVM has 51.6 million fully diluted shares, and a market value of $740 million.

#1. CVM’s drug has far more market potential than GILD’s purchase of IMMU, and 3x to 8x GILD’s TOTAL sales. If bought for $20 Billion / 51.6 million shares = $388 per share = 20x higher.

#2 CVM’s drug’s low potential is 3x BMY’s total sales, justifying a minimum of CELG’s price – a CVM sale for $74 Billion = $1,434 per share = 75x more.

Now children, did you enjoy arithmetic and F-A-C-T-S fun?
Less